| Abstract: | Cicaprost (5-{(E)-(1S,5S,6S,7R)-7-hydroxy-6-(3S,4S)-3-hydroxy-4-methylnona-1,6-diinyl]-bicyclo3.3.0]octan-3-yliden}-3-oxapentanoic acid, ZK, 96 480) is a novel PGI2-derivative, which is chemically stable and not subject to metabolic degradation in rats and cynomolgus monkeys. The pharmacokinetics of Cicaprost were studied in six healthy volunteers (age: 54–74 y) after i.v. infusion (2.1 μ over 60 min) and p.o. dosage (7.6 μg) of the tritiated compound.All treatments were well-tolerated by the test subjects. At the end of the infusion plasma levels of 100 pg/ml were reached, declining biphasically with half-lives of 3–4 min and 64 ± 21 in. Total clearance was 3.8 ± 0.5 ml/min/kg. The oral dosage resulted in peak plasma levels of 251 ± 90 pg/ml occurring at 23 ± 5 min post dose. The terminal half-life in the plasma was 115 ± 30 in. Gastro-intestinal absorption and absolute bioavailability of Cicaprost was complete. After both routes of administration approx. 60 % of dose was excreted with the urine within 24 h, whereas fecal 3H-excretion lasted for several days and accounted for approx. 35 %. Radiochromatography revelaed that Cicaprost was metabolically stable in the plasma and urine. In the feces several degradation products were observed apart from approx. 30 % of the dose fraction being excreted unchanged by that route.The present results demonstrate that Cicaprost is an orally completely bioavailable, metabolically stable PGI2-mimetic which may be an ideal candidate for oral therapy because of its pharmacokinetic characteristics. |
